Mohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses the roles of pertuzumab and neratinib in patients with HER2-positive breast cancer.
Mohammed Rahman, MD
Advertisement
Articles by Mohammed Rahman, MD
Advertisement
Latest Updated Articles
Dr. Rahman on Pertuzumab and Neratinib in HER2+ Breast CancerNovember 6th 2018
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5